David Herrero-Martin

David Herrero-Martin

UNVERIFIED PROFILE

Are you David Herrero-Martin?   Register this Author

Register author
David Herrero-Martin

David Herrero-Martin

Publications by authors named "David Herrero-Martin"

Are you David Herrero-Martin?   Register this Author

18Publications

704Reads

8Profile Views

Cell Death Identification in Anticancer Therapy-Response.

Cancer Res 2015 Sep 18;75(17):3682. Epub 2015 Aug 18.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1540DOI Listing
September 2015

The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Front Oncol 2015 7;5:82. Epub 2015 Apr 7.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387920PMC
April 2015

"(Not) all (dead) things share the same breath": identification of cell death mechanisms in anticancer therapy.

Cancer Res 2015 Mar 27;75(6):913-7. Epub 2015 Feb 27.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3494DOI Listing
March 2015

PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.

Cancer Res 2015 Jan 14;75(1):98-110. Epub 2014 Nov 14.

Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1246DOI Listing
January 2015

Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.

PLoS One 2013 25;8(1):e55072. Epub 2013 Jan 25.

Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0055072PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555977PMC
July 2013

Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Sarcoma 2011 10;2011:352580. Epub 2011 Nov 10.

Children's Cancer Research Institute, St Anna Kinderkrebsforschung, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/352580DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216314PMC
August 2012

The molecular pathogenesis of Ewing's sarcoma.

Cancer Biol Ther 2010 May 12;9(9):655-67. Epub 2010 May 12.

Laboratory of Molecular Pathology of Sarcomas, Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.9.9.11511DOI Listing
May 2010

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

Clin Cancer Res 2006 Jun;12(11 Pt 1):3532-40

Laboratory 20-Molecular Pathology, Centro de Investigación del Cáncer Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1778DOI Listing
June 2006